Q1 2027 Biotech Catalysts: 4 PDUFAs Ranked

Traders are going to spend Q4 2026 chasing the COGT, BBIO, and SVRA cluster. November is the heaviest catalyst month of the year. Meanwhile, Q1 2027 is setting up quietly. Four confirmed PDUFA dates span January through April: a label update for an already-approved ROS1 inhibitor, two first-approval NDAs in niche oncology and rare disease, and one conversion from accelerated to full approval for the only drug in its class. These are the catalysts you can start positioning for now, with the 90-day pre-PDUFA window opening in Q4 for the January date. Prior coverage of the Q4 setup is in the Q4 2026 FDA calendar and the October 2026 catalysts ranked piece. Here is the tradeable rank.

1. CGEM Zipalertinib EGFR Exon 20 NSCLC PDUFA (Feb 27)

Cullinan Therapeutics ($1.08B market cap, $17.73) has the Q1 catalyst with the widest tradeable range: a February 27 PDUFA for zipalertinib in EGFR exon 20 NSCLC, the only first-approval binary on the calendar. The FDA accepted the zipalertinib NDA for EGFR exon 20 insertion-mutated NSCLC after platinum-based chemotherapy, with or without amivantamab, and set a February 27 PDUFA. The NDA is supported by the Phase 2b REZILIENT1 trial, which demonstrated clinically meaningful and durable responses.

Zipalertinib is an oral, irreversible EGFR inhibitor selective for exon 20 insertion mutations. The full pipeline and regulatory picture is covered in the CGEM zipalertinib primer. The competitive set is Johnson & Johnson’s Rybrevant (amivantamab), an IV bispecific antibody approved in 2021. Zipalertinib offers oral dosing, which is a real differentiator in a patient population where every infusion visit is a burden. The REZILIENT1 data needs to show an ORR above 30% and a median PFS above 7 months to be competitive. Rybrevant’s CHRYSALIS trial showed 40% ORR and 8.3-month median PFS in the post-platinum setting. If zipalertinib’s numbers are in that range, oral convenience wins share. If the numbers are meaningfully lower, Rybrevant’s established position holds.

At $1.08B market cap, CGEM is pricing in a reasonable probability of approval. A clean approval with competitive efficacy data re-rates the stock toward $2-3B. A CRL or weak label cuts it in half. The Feb 27 date gives you five months to build a position. The partnership with Taiho (Japan) and the global commercial infrastructure mitigate the launch risk.

ClinicalTrials.gov: REZILIENT1

2. PHVS Deucrictibant HAE PDUFA (Apr 23)

Pharvaris ($2.44B market cap, $34.91) has an NDA accepted for deucrictibant IR capsules for on-demand treatment of HAE attacks, with an April 23 PDUFA. Deucrictibant is a novel oral bradykinin B2 receptor antagonist. If approved, it would be the first oral on-demand therapy for HAE, competing against injectable therapies including Takeda’s TAKHZYRO (lanadelumab, subcutaneous) and Pharming’s Ruconest (IV).

The RAPIDe-3 Phase 3 data is strong: median time to onset of symptom relief was 1.28 hours, median time to complete resolution was 11.95 hours, and the trial met the primary and all 11 secondary endpoints with statistical significance. The NDA covers over 1,300 treated HAE attacks. The safety profile is clean: deucrictibant has been well-tolerated with no new safety signals.

The oral vs injectable differentiation is the thesis. HAE patients currently self-inject or visit infusion centers for on-demand treatment. An oral capsule that resolves attacks in under 12 hours changes the standard of care. The RAPIDe-3 data and competitive picture is detailed in the PHVS deucrictibant primer. Pharvaris is also developing an extended-release formulation for prophylaxis, creating a full oral HAE franchise. At $2.44B market cap, the market is pricing in approval plus some commercial traction. Takeda’s TAKHZYRO generated approximately $1.5B in 2025 revenue. If deucrictibant captures 20-30% of the on-demand market at a premium to injectables, peak sales are $300-500M. The April 23 PDUFA is the first binary, but the bigger catalyst is the prophylactic formulation data, which determines whether Pharvaris can build a full oral franchise or remains an on-demand niche.

The risk: HAE is a small, established market with entrenched injectable incumbents. Oral convenience is not enough if payers restrict access or if the efficacy delta versus injectables is marginal. A clean approval re-rates PHVS toward $3-4B. A CRL or restricted label sends it below $20.

3. BMRN Vosoritide sNDA Conversion PDUFA (Feb 28)

BioMarin ($12.35B market cap, $63.81) has an sNDA accepted to convert VOXZOGO (vosoritide) from accelerated to full approval in children with achondroplasia, with a February 28 PDUFA. VOXZOGO is the only approved medicine for achondroplasia, initially granted accelerated approval in 2021 and used in over 5,000 patients across 50 countries. The sNDA is supported by the largest body of long-term efficacy and safety data for any medicine in achondroplasia, including adult height outcomes from three ongoing studies.

The label conversion matters for payers and guidelines. Full approval strengthens the reimbursement case and supports inclusion in treatment guidelines that currently treat VOXZOGO as an option rather than a standard of care. The regulatory pathway and data package are covered in the BMRN vosoritide PDUFA primer. But the stock impact is limited. At $12.35B market cap, BioMarin’s valuation is driven by its enzyme replacement therapy franchise (Vimizim, Naglazyme, Palynziq) and the PKU gene therapy pipeline, not by the VOXZOGO label conversion. The conversion is a regulatory milestone, not a stock-mover. If VOXZOGO were 30% of BioMarin’s revenue, the approval would matter. It is closer to 10-15%.

The more important BioMarin catalyst is pipeline execution, not label conversion. The BMN-401 gene therapy discontinuation in August 2026 (a $270M write-off) was a reminder that BioMarin’s pipeline credibility is uneven. Hold BMRN for the enzyme replacement cash flows, not the VOXZOGO PDUFA. The Feb 28 date is a rubber stamp.

4. NUVB IBTROZI sNDA Label Update PDUFA (Jan 4)

Nuvation Bio ($2.32B market cap, $6.60) has an sNDA accepted with a January 4 PDUFA for updated IBTROZI (taletrectinib) efficacy data in ROS1+ NSCLC. IBTROZI was fully approved in June 2025 for ROS1+ NSCLC across lines of therapy. This sNDA includes an additional 10 months of data from TRUST-I and TRUST-II: median DOR of 49.7 months and median PFS of 49.6 months in TKI-naive patients, and mDOR of 19.4 months in TKI-pretreated patients.

The label update is a housekeeping catalyst, not a thesis. The long-term efficacy data and regulatory timeline are detailed in the NUVB IBTROZI primer. The data reinforces IBTROZI’s position as the standard of care in ROS1+ NSCLC, but the drug is already approved and launching. The sNDA adds long-term follow-up to the label; it does not open a new indication or expand the addressable population. Nuvation’s stock is driven by launch execution and the pipeline (safusidenib, the DDC program), not by a label update.

If you are trading NUVB, the January 4 date is a non-event. The real catalysts are the EU approval decision (MAA validated March 2026, standard review) and the adjuvant TRUST-IV Phase 3 readout (primary completion 2030). Hold NUVB for the ROS1 franchise build-out, not the label update.

On-Deck: May 2027 Catalysts. Just beyond Q1, two PDUFA dates are worth noting now. Axsome Therapeutics’ AXS-12 for narcolepsy cataplexy has a May 1 PDUFA. Bristol Myers Squibb’s MeziKd (mezigdomide) for relapsed myeloma has a May 13 PDUFA. Both are larger catalysts than anything in Q1. If you are planning a Q1-to-Q2 catalyst rotation, start the AXSM and BMY research now.

Risks

Three of the four Q1 catalysts are label updates or conversions, not first approvals. NUVB and BMRN are incremental, not transformative. PHVS in on-demand HAE is arguably incremental too in a market dominated by injectable therapies. Only CGEM is a genuine first-approval binary. The Q1-into-Q2 rotation compounds the problem: if AXSM narcolepsy data and BMY mezigdomide data strengthen before April, capital rotates out of Q1 names and into Q2 positioning early. Between now and then, the wide spacing, with one PDUFA in January, two in February, and one in late April, means long dry periods between binary events.

Verdict

Ranked by tradeable binary risk-reward: CGEM (genuine first approval, oral convenience vs IV incumbent, $1.08B market cap with room to run), PHVS (oral HAE on-demand, strong Phase 3 data, but market is already pricing in approval at $2.44B), BMRN (rubber stamp, $12.35B market cap limits stock impact), NUVB (label update on an already-approved drug, non-event).

CGEM is the Q1 trade. Start building a position in Q4 2026. PHVS is a hold through the April PDUFA but size it below CGEM because the market cap already reflects approval probability. BMRN and NUVB are hand-offs: stay long for the franchise cash flows, but do not trade the PDUFA dates.